ICBMT 2024. ICBMT 2024. THE 8th INTERNATIONAL CONGRESS OF BMT 2024. THE 29th ANNUAL CONGRESS OF KSBMT.

Moving Forward into the New Era of HSCT and Cellular Therapy

SEPTEMBER 26(Thu) - 28(Sat), 2024. BEXCO, BUSAN, KOREA
HOME

Scientific Program

SELECT AND VIEW SESSIONS OF YOUR CHOICE
Search

Satellite Symposium 1

Sep. 27 (Fri), 08:30-09:00 		Room A
(2F)
Chair(s) Seok Lee (The Catholic University of Korea)
  • Makoto Onizuka

    08:30-09:00

    Ponatinib and Chemotherapy for Adult Patients with Newly Diagnosed Ph+ ALL Based from the PhALLCON Trial

    Makoto Onizuka

    Tokai University School of Medicine, Japan

Oral Presentation 5

 Room A
(2F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Soo-Mee Bang (Seoul National University College of Medicine)
Sung Hwa Bae (Daegu Catholic University School of Medicine)
Speaker(s) 09:00-09:10 The Prognostic Impact of Allogeneic Stem Cell Transplantation on Patients with Myelodysplastic Syndromes/Neoplasms Wan-Hsuan Lee (National Taiwan University Hospital)
09:10-09:20 Results of Allogeneic Stem Cell Transplantation in Advanced Myelofibrosis Jong Hyuk Lee (The Catholic University of Korea)
09:20-09:30 Pure Red Cell Aplasia in Acute Myeloid Leukemia Patients after ABO Mismatched HSCT So Yeon Park (The Catholic University of Korea)
09:30-09:40 Efficacy and Safety of Salvage Chemotherapy Regimens in Relapsed or Refractory Acute Myeloid Leukemia Hun Seok Choi (Yonsei University College of Medicine)
09:40-09:50 Real World Transplantation Outcomes of Myelofibrosis Treated with Pre-transplant Splenic Irradiation Yu-Sung Chang (National Taiwan University Hospital)
09:50-10:00 Venetoclax/Azacitidine Followed by Allogeneic Transplantation Is as Good as Intensive Chemotherapy Followed by Allogeneic Transplantation for Patients of AML at First Remission Su-Peng Yeh (China Medical University Hospital)

Oral Presentation 6

 Room B
(2F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Eun Sun Yoo (Ewha Womans University College of Medicine)
Jun Eun Park (Korea University College of Medicine)
Speaker(s) 09:00-09:10 Successful Outcomes of Haploidentical Family Donor Hematopoietic Cell Transplantation in Pediatric Severe Aplastic Anemia Suejung Jo (The Catholic University of Korea)
09:10-09:20 Outcome of Allogenic Hematopoietic Stem Cell Transplantation in Leukodystrophies: A Single-Center Experience over 15 Years Hyun Jin Park (Seoul National University College of Medicine)
09:20-09:30 Comparable Outcome of Myeloablative Total Body Irradiation Conditioning and Chemo-conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing First Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Korean Registry-Based Study Kyung Taek Hong (Seoul National University College of Medicine)
09:30-09:40 Feasibility of Tandem Conditioning-Based Myeloablative HSCT for Pediatric Patients with Relapsed/Refractory Myeloid Hematologic Malignancies Jae Won Yoo (The Catholic University of Korea)
09:40-09:50 Response-Adapted Consolidation Therapy Strategy for Patients with Metastatic High-risk Neuroblastoma: Results of the SMC NB-2014 Study Hee Won Cho (Sungkyunkwan University School of Medicine)
09:50-10:00 Introduction of Bone Marrow Transplantation in Children in Uzbekistan Khilola Rustamova (Scientific and Practical Center of Pediatric Oncology, Hematology and Immunology of Uzbekistan)

Oral Presentation 7

 Room C
(1F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Hye Lim Jung (Sungkyunkwan University School of Medicine)
Yong Park (Korea University College of Medicine)
Speaker(s) 09:00-09:10 Graft-versus-Host Disease Prophylaxis with Post-Transplant Cyclophosphamide Better Preserves Regulatory T Cell Bu-Yeon Heo (Chungnam National University College of Medicine)
09:10-09:20 The Expression of TIM3 on Marrow-Infiltrating T cells Is Increased in Patients with Blood Cancers Who Relapse Early after Hematopoietic Stem Cell Transplantation Thi Thuy Duong Pham (Chungnam National University College of Medicine)
09:20-09:30 Mesenchymal Stem Cell-Derived Exosomes for Enhanced Proliferation of CD34+ Cells Kunye Kwak (Korea University College of Medicine)
09:30-09:40 Phase II Trial of Imatinib Mesylate in Patients with Idiopathic Hypereosinophilic Syndrome Dong Hyun Kim (Seoul National University College of Medicine)
09:40-09:50 Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation Jinhang Kim (The Catholic University of Korea)
09:50-10:00 Novel Mechanisms of Leukemogenesis: Genome Reorganization by TET Loss of Function Myunggon Ko (Ulsan National Institute of Science and Technology)

Oral Presentation 8

 Room D
(1F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Seok-Goo Cho (The Catholic University of Korea)
Jeong A Kim (The Catholic University of Korea)
Speaker(s) 09:00-09:10 Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) against Multiple Myeloma Manh Cuong Vo (Chonnam National University Medical School)
09:10-09:20 CAR-T Therapy in Taiwan: Outcomes and Adverse Events from a National Registry Analysis Xavier Cheng-Hong Tsai (National Taiwan University Hospital)
09:20-09:30 Risk-Stratification for DLBCL Patients Receiving ASCT in the Era of New Targeted Drugs: A Real-World Study in China Wen-Xuan Huo (Peking University People's Hospital)
09:30-09:40 Single-cell RNA Analysis of Peripheral T Cells in Chronic Lymphocytic Leukemia Relapse after Chemotherapy or Allogeneic Transplantation Ho Cheol Jang (Chonnam National University Medical School)
09:40-09:50 Prognostic Factors and Treatment Outcome of Allo-SCT for Lymphoid Malignancy Hyungsoon Kim (Yonsei University College of Medicine)
09:50-10:00 Efficacy and Safety of Cytokine-Induced Killer Cells Infusion Combined with TRUXIMA as Post-Remission Therapy in Old Aged High-Risk Diffuse Large B Cell Lymphoma Patients Gi June Min (The Catholic University of Korea)

Plenary Session 3

Sep. 27 (Fri), 10:20-11:00 		Room A
(2F)
Chair(s) Hyeoung-Joon Kim (Chonnam National University Medical School)
  • Hee-Je Kim

    10:20-11:00

    New Horizons in the Treatment of Acute Myeloid Leukemia

    Hee-Je Kim

    The Catholic University of Korea, Korea

Presidential Symposium

Sep. 27 (Fri), 11:00-11:40 		Room A
(2F)
Chair(s) Je-Jung Lee (Chonnam National University Medical School)
  • Nicolaus Kröger

    11:00-11:40

    Future Perspectives of HSCT in the Cellular Immunotherapy Era

    Nicolaus Kröger

    University Medical Center Hamburg-Eppendorf, Germany

Luncheon Symposium 6

Sep. 27 (Fri), 11:50-12:30 		Room A
(2F)
Chair(s) Chul Won Jung (Sungkyunkwan University School of Medicine)
  • Vikas Gupta

    11:50-12:30

    How to Optimize Outcomes of Transplant in Myelofibrosis?

    Vikas Gupta

    Princess Margaret Cancer Centre, Canada

Luncheon Symposium 7

Sep. 27 (Fri), 11:50-12:30 		Room B
(2F)
Chair(s) Hee-Je Kim (The Catholic University of Korea)
  • Sung-Yeon Cho

    11:50-12:30

    Optimal Managing of IMD in the Haematology Unit: Role of Vfend®, Cresemba®

    Sung-Yeon Cho

    The Catholic University of Korea, Korea

Luncheon Symposium 8

Sep. 27 (Fri), 11:50-12:30 		Room C
(1F)
Chair(s) Je-Hwan Lee (University of Ulsan College of Medicine)
  • Bipin Savani

    11:50-12:30

    Management of GVHD in 2024- From Steroid-to-steroid Sparing Approach

    Bipin Savani

    Vanderbilt University Medical Center, USA

Luncheon Symposium 9

Sep. 27 (Fri), 11:50-12:30 		Room D-1
(1F)
Chair(s) Ho-Jin Shin (Pusan National University School of Medicine)
  • Hyewon Lee

    11:50-12:30

    CMV Prophylaxis with Letermovir in Allo HSCT - Extended Use in High Risk Patients

    Hyewon Lee

    National Cancer Center, Korea

Luncheon Symposium 10

Sep. 27 (Fri), 11:50-12:30 		Room D-2
(1F)
Chair(s) Jin Seok Kim (Yonsei University College of Medicine)
  • Jeff Szer

    11:50-12:30

    Remaining Unmet Needs in Current Treatment and a New Treatment Option in PNH

    Jeff Szer

    Royal Melbourne Hospital, Australia

Scientific Session 5

Sep. 27 (Fri), 12:40-14:10 		Room A
(2F)
Chair(s) Sang Kyun Sohn (Kyungpook National University School of Medicine)
Joon Seong Park (Ajou University School of Medicine)
  • Melody Smith

    12:40-13:10

    Evaluating the Regulatory Mechanisms for the Impact of the Intestinal Microbiome on Chimeric Antigen Receptor T Cells

    Melody Smith

    Stanford University, USA

  • Kentaro Fukushima

    13:10-13:40

    Prolonged Gut Microbial Alterations in Post-Transplant Survivors of Allogeneic Hematopoietic Stem Cell Transplantation

    Kentaro Fukushima

    Osaka University Graduate School of Medicine, Japan

  • Armin Rashidi

    13:40-14:10

    Fecal Microbiota Transplantation in the Prophylactic Setting after Allogeneic Hematopoietic Cell Transplantation

    Armin Rashidi

    Fred Hutch Cancer Center, USA

Scientific Session 6

Sep. 27 (Fri), 12:40-14:10 		Room B
(2F)
Chair(s) Hyeon Jin Park (National Cancer Center)
Duck Cho (Sungkyunkwan University School of Medicine)
  • Peter Lang

    12:40-13:10

    Haploidentical HCT for Neuroblastoma

    Peter Lang

    University Children’s Hospital Tuebingen, Germany

  • Ho Joon Im

    13:10-13:40

    Graft Engineering and Adoptive Cell Therapy

    Ho Joon Im

    University of Ulsan College of Medicine, Korea

  • Junsang Doh

    13:40-14:10

    Modulating NK Cell Synapses for the Improvement of NK Cell Therapy

    Junsang Doh

    Department of Materials Science and Engineering, Seoul National University, Korea

Education Session 2

Sep. 27 (Fri), 12:40-14:10 		Room C
(1F)
Chair(s) Chul Won Choi (Korea University Guro Hospital)
Sung-Yong Kim (Konkuk University School of Medicine)
  • Sung-Eun Lee

    12:40-13:10

    Considerations before HSCT for Patients with MF

    Sung-Eun Lee

    The Catholic University of Korea, Korea

  • Junshik Hong

    13:10-13:40

    Considerations about HSCT for Patients with MF (Donor, Conditioning Regimen, Engraftment, GVHD Prophylaxis)

    Junshik Hong

    Seoul National University College of Medicine, Korea

  • Kyoung Ha Kim

    13:40-14:10

    Is HSCT Still the Effective Treatment for CML?

    Kyoung Ha Kim

    Soonchunhyang University College of Medicine, Korea

Scientific Session 7

Sep. 27 (Fri), 12:40-14:10 		Room D
(1F)
Chair(s) Chang-Ki Min (The Catholic University of Korea)
Hyeon-Seok Eom (National Cancer Center)
  • Paul G. Richardson

    12:40-13:10

    Next-Generation Novel Therapies in Multiple Myeloma

    Paul G. Richardson

    Dana-Farber Cancer Institute, USA

  • John Wagner

    13:10-13:40

    CAR-19 Expressing Regulatory T Cells to Enhance GVHD-free, Relapse-free Survival in Patients with High Risk CD19+ Hematological Malignancy: Rationale and Developmental Pathway

    John Wagner

    University of Minnesota, USA

  • Changsong Qi

    13:40-14:10

    CAR-T Cell Therapy in Gastrointestinal Cancers

    Changsong Qi

    Peking University Cancer Hospital & Institute, China

Joint Symposium 3

Sep. 27 (Fri), 14:20-16:00 		Room A
(2F)
Chair(s) Seong Kyu Park (Soonchunhyang University College of Medicine)
Anna Sureda (Catalan Institute of Oncology)
  • Annalisa Ruggeri

    14:20-14:45

    Current Status of Alternative Donor Transplantation Compared to Conventional Donor: EBMT Perspectives

    Annalisa Ruggeri

    IRCCS San Raffaele Hospital, Italy

  • Avichai Shimoni

    14:45-15:10

    KIR-Mismatch and Transplantation Outcome in Myeloid vs. Lymphoid Disease

    Avichai Shimoni

    Chaim Sheba Medical Center, Israel

  • Seo-Yeon Ahn

    15:10-15:35

    Outcome of Alternative Donor Transplantation in AML and MDS in Korea

    Seo-Yeon Ahn

    Chonnam National University Medical School, Korea

  • Jae Ho Yoon

    15:35-16:00

    Alternative Donor Hematopoietic Cell Transplantation (HCT): Korean Experiences and Optimization of Cord Blood and Haploidentical Donor HCT in Adult ALL

    Jae Ho Yoon

    The Catholic University of Korea, Korea

Debate Session 1

Sep. 27 (Fri), 14:20-15:10 		Room B
(2F)
Chair(s) Jin Seok Kim (Yonsei University College of Medicine)
  • Ji Hyun Lee

    14:20-14:35

    No Upfront ASCT

    Ji Hyun Lee

    Dong-A University College of Medicine, Korea

  • Myung-won Lee

    14:35-14:50

    Upfront ASCT

    Myung-won Lee

    Chungnam National University College of Medicine, Korea

  • 　

    14:50-15:10

    Debate

    　

    　, 　

Education Session 3

Sep. 27 (Fri), 14:20-15:50 		Room C
(1F)
Chair(s) Jae-Yong Kwak (Jeonbuk National University Medical School)
Hyoung Soo Choi (Seoul National University College of Medicine)
  • Yoshihiro Inamoto

    14:20-14:50

    Late Effect of Transplantation

    Yoshihiro Inamoto

    Fujita Health University School of Medicine, Japan

  • Hye Yoon Park

    14:50-15:20

    Post-HSCT Psychological Impact and Care

    Hye Yoon Park

    Department of Psychiatry, Seoul National University College of Medicine, Korea

  • Yoo Jin Lee

    15:20-15:50

    Fertility after Allogeneic Hematopoietic Stem Cell Transplantation

    Yoo Jin Lee

    University of Ulsan College of Medicine, Korea

Scientific Session 8

Sep. 27 (Fri), 14:20-16:05 		Room D
(1F)
Chair(s) Hong Ghi Lee (Konkuk University Medical Center)
Yeun Jun Chung (The Catholic University of Korea)
  • Stephanie Lee

    14:25-14:50

    Transplants from Unrelated Donors in the United States: Where We Are, Where We Are Going

    Stephanie Lee

    Fred Hutch Cancer Center, USA

  • Nicolaus Kröger

    14:50-15:15

    Transplants from Unrelated Donors in Europe: Where We Are and Where We Are Going

    Nicolaus Kröger

    University Medical Center Hamburg-Eppendorf, Germany

  • Shinichiro Okamoto

    15:15-15:40

    Designing the Future of Unrelated Donor Registries and Transplantation - JMDP Perspective -

    Shinichiro Okamoto

    Keio University School of Medicine, Japan

  • Keon Hee Yoo

    15:40-16:00

    Unrelated Donor Hematopoietic Stem Cell Transplantation in Korea

    Keon Hee Yoo

    Sungkyunkwan University School of Medicine, Korea

Debate Session 2

Sep. 27 (Fri), 15:10-16:00 		Room B
(2F)
Chair(s) Kyung-Nam Koh (University of Ulsan College of Medicine)
  • Hee Young Ju

    15:10-15:25

    Cons: Upfront HSCT Is Not Needed

    Hee Young Ju

    Sungkyunkwan University School of Medicine, Korea

  • Seung Min Hahn

    15:25-15:40

    Pro: Upfront HSCT Is Needed

    Seung Min Hahn

    Yonsei University College of Medicine, Korea

  • 　

    15:40-16:00

    Debate

    　

    　, 　

Joint Symposium 4

Sep. 27 (Fri), 16:30-18:10 		Room A
(2F)
Chair(s) Je-Jung Lee (Chonnam National University Medical School)
Chi-Cheng Li (Hualien Tzu Chi Hospital)
  • Sung-Hoon Jung

    16:30-16:55

    Current Role of ASCT in Multiple Myeloma

    Sung-Hoon Jung

    Chonnam National University Medical School, Korea

  • Nobuhiro Tsukada

    16:55-17:20

    Autologous Stem Cell Mobilization and Transplantation for Multiple Myeloma - Current Status and Future Perspectives in Japan -

    Nobuhiro Tsukada

    Japanese Red Cross Medical Center, Japan

  • Xiao-Dong Mo

    17:20-17:45

    Current Status of ASCT and the Role of CAR-T Cell Therapy in Managing Myeloma in China

    Xiao-Dong Mo

    Peking University People's Hospital, China

  • Jeffrey SY Huang

    17:45-18:10

    Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma in Taiwan

    Jeffrey SY Huang

    National Taiwan University Hospital, Taiwan

Scientific Session 9

Sep. 27 (Fri), 16:40-18:10 		Room B
(2F)
Chair(s) Yoo Hong Min (Yonsei University School of Medicine)
Kyoo-Hyung Lee (Ewha Womans University College of Medicine)
  • Gabriele Casirati

    16:40-17:10

    Base Editing of Surface Epitopes to Empower Cancer Immunotherapy and Beyond

    Gabriele Casirati

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA

  • Johannes Schetelig

    17:10-17:40

    Is AML Remission Induction Prior to alloHCT Necessary?

    Johannes Schetelig

    University Hospital Carl Gustav Carus Dresden, Germany

  • Dong-Yeop Shin

    17:40-18:10

    Salvage HSCT in AML: Strategies for Improvement

    Dong-Yeop Shin

    Seoul National University College of Medicine, Korea

Scientific Session 10

Sep. 27 (Fri), 16:40-18:10 		Room C
(1F)
Chair(s) Hyoung Jin Kang (Seoul National University College of Medicine)
So Ra Park (Regenerative Medicine Acceleration Foundation)
  • Daehyeon Baek

    16:40-17:10

    Regulatory Science Updates for Advanced Biological Products in Korea

    Daehyeon Baek

    Cell&Gene Therapy Products Division/MFDS, Korea

  • So Ra Park

    17:10-17:40

    Opportunities and Challenges on Clinical Translation of Cell & Gene Therapy in Korea

    So Ra Park

    Regenerative Medicine Acceleration Foundation, Korea

  • Michael Verneris

    17:40-18:10

    From Lab to Bedside: Navigating FDA Regulations for Novel Cell Therapies in the US

    Michael Verneris

    Children's Hospital Colorado, USA

Education Session 4

Sep. 27 (Fri), 16:40-18:10 		Room D
(1F)
Chair(s) Sung-Hyun Kim (Dong-A University College of Medicine)
Jung Woo Han (Yonsei University College of Medicine)
  • Seung-Ji Kang

    16:40-17:10

    Vaccination Guidelines after Hematopoietic Cell Transplantation

    Seung-Ji Kang

    Chonnam National University Medical School, Korea

  • Sung-Yeon Cho

    17:10-17:40

    Cytomegalovirus in Hematopoietic Cell Transplantation: Prophylaxis & Treatment

    Sung-Yeon Cho

    The Catholic University of Korea, Korea

  • Dong Won Baek

    17:40-18:10

    Appropriate Screening for cGVHD

    Dong Won Baek

    Kyungpook National University School of Medicine, Korea